SCM
KNSA icon

Sterling Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Sterling Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.53K Buy
+149
New +$7.73K ﹤0.01% 2245
2025
Q2 		– Sell
-44
Closed -$977 – 3328
2025
Q1 		$977 Buy
44
+6
+16% +$123 ﹤0.01% 2827
2024
Q4 		$752 Hold
38
– – ﹤0.01% 2988
2024
Q3 		$950 Buy
+38
New +$926 ﹤0.01% 2557

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Sterling Capital Management's KNSA Position: Q2 2026 in Review

Sterling Capital Management opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q2 2026: 149 shares worth $9.53K. The stake represents ﹤0.01% of the portfolio and ranks #2245 among its holdings. This is a return to the name: Sterling Capital Management previously reported a position in KNSA as recently as Q1 2025.

Sterling Capital Management first reported a position in KNSA in Q3 2024 and has held it in 4 quarters since. 267 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Sterling Capital Management held 149 shares of Kiniksa Pharmaceuticals worth $9.53K as of Q2 2026.
  • Kiniksa Pharmaceuticals was a new Sterling Capital Management position in Q2 2026.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2245 holding.
  • Sterling Capital Management first reported a position in Kiniksa Pharmaceuticals in Q3 2024 and has held it in 4 quarters since.
  • 267 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.